Given that intestinal mucosal barrier dysfunction represents a fundamental pathogenic mechanism in IBD, CDC14A-mediated epithelial cell regulation may offer therapeutic potential for enhancing barrier function. The gene discussed is CDC14A; the disease is inflammatory bowel disease.